Few medications have had such a meteoric rise as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound), the GLP-1-based treatments for obesity that have captivated society and quickly become ...

Jess Loren remembers loving the taste of Cap'n Crunch cereal. Coca-Cola. Snickers bars. But now, instead of a sweetness, "they taste bland," she says. Flavors are noticeably muted since she started a ...

GLP-1 usage is on the rise, and researchers are looking for other health benefits associated with the drug, including its effects on bladder health. But as GLP-1s rise in popularity, so do nicknames ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...

Your pet dog or cat might soon be a chubby little munchkin no more. Welcome to the burgeoning era of — we swear we’re not making this up — “ozempets,” in which your servile critters might shed some ...

The World Health Organization conditionally recommends the use of GLP-1 drugs, including tirzepatide, marketed as Mounjaro and Zepbound, for obesity treatment. Peter Dazeley via Getty Images The World ...

XReal has launched a new entry-level AR glasses model in Japan, the XReal 1S. It slots below the XReal One Pro announced earlier this year and is the first pair of consumer AR glasses to offer ...

XREAL is wrapping up 2025 with the launch of a new entry-level AR glasses model, the XREAL 1S. It sits below the more expensive XREAL One Pro (announced in July) in the lineup and is the first in the ...

If you visit a fast-food chain in the next few years, expect the menu to look a little less gluttonous. In between the usual deep-fried options, industry observers anticipate more offerings that come ...

When Chevese Turner first discussed Ozempic with her doctor to treat her diabetes, she was both worried and relieved. Finally, “there was something effective that [was] going to address my diabetes,” ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.